Literature DB >> 29675965

Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.

Ryuichiro Sawada1,2, Yuna Ku1,3, Masayuki Akita1,4, Kyoko Otani1, Kohei Fujikura1, Tomoo Itoh1, Tetsuo Ajiki4, Takumi Fukumoto4, Yoshihiro Kakeji2, Yoh Zen1.   

Abstract

AIMS: The aim of the present study was to elucidate the clinicopathological significance of interleukin (IL)-6 and IL-33 expression in intrahepatic cholangiocarcinomas (iCCAs) and perihilar cholangiocarcinomas (pCCAs). METHODS AND
RESULTS: IL-6 and IL-33 mRNA expression levels were examined in iCCAs (n = 55) and pCCAs (n = 32) by the use of quantitative real-time polymerase chain reaction and a highly sensitive in-situ hybridisation protocol (RNAscope), and expression levels were correlated with clinicopathological features. According to a recently proposed classification scheme, iCCAs were separated into small-duct (n = 33) and large-duct (n = 22) types. IL-6 and IL-33 expression levels were higher in large-duct iCCAs and pCCAs than in small-duct iCCAs, and there was a positive correlation between the expression levels of these cytokines. Double in-situ hybridisation/immunostaining showed that IL-6 mRNA was expressed in actin-positive (myo)fibroblasts, whereas IL-33 mRNA was mainly produced by CD31-positive endothelial cells. With the average expression level as a cut-off point, cases were classified as IL-6high and IL-6low or IL-33high and IL-33low . In the combined cohort of large-duct iCCAs and pCCAs, IL-6high and IL-6low cholangiocarcinomas shared many features, whereas IL-33high cases had less aggressive characteristics than IL-33low cases, as shown by lower tumour marker concentrations, smaller tumour sizes, less common vascular invasion, lower pT stages, and higher lymphocyte/monocyte ratios in blood. KRAS mutations were slightly less common in IL-33high cases than in IL-33low cases (9% versus 29%; P = 0.061). The strong expression of IL-33 in tissue appeared to be an independent favourable prognostic factor.
CONCLUSIONS: IL-33high cholangiocarcinomas may represent a unique, less aggressive carcinogenetic process of the large bile ducts.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-33; IL-6; cholangiocarcinoma; microenvironment; prognosis

Mesh:

Substances:

Year:  2018        PMID: 29675965     DOI: 10.1111/his.13633

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

Review 1.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

2.  Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis.

Authors:  Kulthida Vaeteewoottacharn; Ryusho Kariya; Phattarin Pothipan; Sawako Fujikawa; Chawalit Pairojkul; Sakda Waraasawapati; Kazuhiko Kuwahara; Chaisiri Wongkham; Sopit Wongkham; Seiji Okada
Journal:  Transl Oncol       Date:  2018-11-09       Impact factor: 4.243

3.  Hedgehog Signaling Modulates Interleukin-33-Dependent Extrahepatic Bile Duct Cell Proliferation in Mice.

Authors:  Nataliya Razumilava; Junya Shiota; Nureen H Mohamad Zaki; Ramon Ocadiz-Ruiz; Christine M Cieslak; Kais Zakharia; Benjamin L Allen; Gregory J Gores; Linda C Samuelson; Juanita L Merchant
Journal:  Hepatol Commun       Date:  2018-12-11

Review 4.  Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.

Authors:  Hayato Nakagawa; Yuki Hayata; Tomoharu Yamada; Satoshi Kawamura; Nobumi Suzuki; Kazuhiko Koike
Journal:  Int J Mol Sci       Date:  2018-06-12       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.